n.a. (BRLI)

34.61
0.34 0.97
NASDAQ
Prev Close 34.95
Open 34.74
Day Low/High 34.03 / 34.96
52 Wk Low/High /
Volume 423.74K
Exchange NASDAQ
Div & Yield N.A. (N.A)
Bio-Reference Laboratories Inc Stock Downgraded (BRLI)

Bio-Reference Laboratories Inc Stock Downgraded (BRLI)

Bio-Reference Laboratories (Nasdaq:BRLI) has been downgraded by TheStreet Ratings from from a buy to hold.

Ratings Changes Today

Upgrades: CZFC, NPSP, SCCO, STR, TWI Downgrades: BRLI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Bio-Reference Laboratories Stock Sees Short Interest Decline 10.2%

Bio-Reference Laboratories Stock Sees Short Interest Decline 10.2%

The most recent short interest data has been released by the NASDAQ for the 12/31/2013 settlement date, which shows a 817,530 share decrease in total short interest for Bio-Reference Laboratories, Inc. , to 7,240,166, a decrease of 10.15% since 12/13/2013.

Get Mad, Then Average Down

Get Mad, Then Average Down

Sometimes a buy goes against you, even if the fundamentals are solid.

Bio-Reference Laboratories, Inc. Announces Record Quarterly Revenues And Record Annual Revenues And Earnings Despite Significant 4th Quarter Headwinds

Bio-Reference Laboratories, Inc. Announces Record Quarterly Revenues And Record Annual Revenues And Earnings Despite Significant 4th Quarter Headwinds

The Company Displayed Strong Growth But Faced Significant Reimbursement Pressure From Commercial Payers and Quarterly Expenses Associated With the Integration of Acquisitions and New Growth Opportunities

5 Hated Earnings Stocks You Should Love

5 Hated Earnings Stocks You Should Love

These heavily shorted stocks that could get squeezed much higher if they report positive earnings this week.

Stay Away From This Laboratory

Stay Away From This Laboratory

LabCorp will continue to underperform in this challenging business environment, with little revenue growth and declining earnings.

Don't Pass on This Test Company

Don't Pass on This Test Company

Quest Diagnostics -- and others in this beaten-down sector -- are excellent trading vehicles.

Bio-Reference Labs Rides a Demographic Wave

Bio-Reference Labs Rides a Demographic Wave

As more people get health insurance, this stock should prove to be a steady grower.

Bio-Reference Laboratories Becomes Oversold (BRLI)

Bio-Reference Laboratories Becomes Oversold (BRLI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Why Bio-Reference Labs (BRLI) Crashed Wednesday

Why Bio-Reference Labs (BRLI) Crashed Wednesday

Shares of Bio-Reference Labs (BRLI) were pounded on Wednesday after the company failed to impress with fourth-quarter and full-year guidance.

4 Stocks Underperforming Today In The Health Services Industry

4 Stocks Underperforming Today In The Health Services Industry

TheStreet highlights 4 stocks pushing the health services industry lower today.

BioReference Laboratories, Inc. Provides Guidance For FY13 And Q4FY13 Anticipated Results

BioReference Laboratories, Inc. Provides Guidance For FY13 And Q4FY13 Anticipated Results

Company Identifies Multiple Factors Adversely Affecting Results

New Lifetime High For Bio-Reference Labs (BRLI)

New Lifetime High For Bio-Reference Labs (BRLI)

Trade-Ideas LLC identified Bio-Reference Labs (BRLI) as a new lifetime high candidate

New Lifetime High Reached By Bio-Reference Labs (BRLI)

New Lifetime High Reached By Bio-Reference Labs (BRLI)

Trade-Ideas LLC identified Bio-Reference Labs (BRLI) as a new lifetime high candidate

BioReference Laboratories, Inc. Sued By Myriad Genetics, Confident In Its Position

BioReference Laboratories, Inc. Sued By Myriad Genetics, Confident In Its Position

Company Not Yet Served, But Has Been Prepared for an Expected Action

BioReference Laboratories, Inc. Reports Sustained Growth On Strong Quarterly Results

BioReference Laboratories, Inc. Reports Sustained Growth On Strong Quarterly Results

Company Maintains Growth Trajectory Through Q3FY13

5 Stock Set to Soar on Bullish Earnings

5 Stock Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

BioReference Laboratories, Inc. Announces Strategic Acquisition Of Edge BioSystems' Service Business

BioReference Laboratories, Inc. Announces Strategic Acquisition Of Edge BioSystems' Service Business

Acquisition Will Provide Added Genetic Sequencing and R&D Capability for GeneDx

Bio-Reference Laboratories (BRLI) Shares Cross Above 200 DMA

Bio-Reference Laboratories (BRLI) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Bio-Reference Laboratories, Inc. crossed above their 200 day moving average of $27.52, changing hands as high as $27.75 per share.

BioReference Laboratories, Inc. Announces Strategic Acquisition

BioReference Laboratories, Inc. Announces Strategic Acquisition

California Acquisition Provides West Coast Presence

Bio-Reference Laboratories Getting Very Oversold (BRLI)

Bio-Reference Laboratories Getting Very Oversold (BRLI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pulling The Health Services Industry Downward

TheStreet highlights 3 stocks pushing the health services industry lower today.

Court Ruling Boosts Bio-Reference

Court Ruling Boosts Bio-Reference

Bio-Reference Labs CEO Dr. Marc Grodman says the Supreme Court ruling against human gene patents means big things for the testing industry.

Notable Two Hundred Day Moving Average Cross - BRLI

Notable Two Hundred Day Moving Average Cross - BRLI

In trading on Thursday, shares of Bio-Reference Laboratories, Inc. crossed below their 200 day moving average of $27.93, changing hands as low as $27.87 per share.

Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done

Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done

Analyst downgrade Myriad following a Supreme Court ruling invalidating patents on human genese.

Short Interest Moves 17% Lower For BRLI

Short Interest Moves 17% Lower For BRLI

The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 1,774,692 share decrease in total short interest for Bio-Reference Laboratories, Inc. , to 8,690,169, a decrease of 16.96% since 05/15/2013.